Navigation Links
Scientists uncover how superbug Staph aureus resists our natural defenses
Date:3/24/2008

Researchers at the University of Washington have uncovered how the bacterium Staphylococcus aureus, including the notorious MRSA (methicillin-resistant Staph aureus) superbug strains, resists our body's natural defenses against infection. The work, which was featured on the cover of the March 21 issue of Science, could lead to new ways to fight the bacteria.

Dr. Ferric Fang, UW professor of laboratory medicine and microbiology, and his UW colleagues Dr. Anthony Richardson and Dr. Stephen Libby set out to determine what makes Staph aureus a better pathogen than other bacteria. They focused on a chemical compound called nitric oxide (NO), a natural antibiotic that our cells excrete to protect us from pathogens. For most bacteria, NO creates an environment that keeps invading microbes from undergoing respiration or fermentation, vital chemical processes that allow bacteria to grow.

The researchers found that Staph aureus has a mechanism that allows it to produce lactic acid in the presence of NO, which allows it to maintain its chemical balance and keep growing and thriving in the harsh host environment. When Staph aureus is exposed to NO, it produces the novel enzyme responsible for lactic acid production, along with another enzyme that converts NO to non-toxic products. NO is commonly found in the nose and nasal passages, and is meant to protect people against disease-causing microbes. But Staph aureus is commonly found in the nose despite the presence of NO, the researchers explained.

When the researchers modified Staph aureus to take away its ability to make lactic acid, the bacteria could no longer tolerate NO. The modified bacteria also lost their ability to survive in host immune cells and cause lethal disease in mice.

"MRSA has become an enormous public health problem, by causing both hospital- and community-acquired infections," explained Fang. "Staph aureus has already colonized about one-third of the world's popul
'/>"/>

Contact: Justin Reedy
jreedy@u.washington.edu
206-685-0382
University of Washington
Source:Eurekalert

Page: 1 2

Related medicine news :

1. New prion protein discovered by Canadian scientists may offer insight into mad cow disease
2. Scientists Probe Sepsis Deadly Secrets
3. Scientists puzzled by severe allergic reaction to cancer drug in the middle Southern US
4. Scientists Develop Natural Protection for Stored Foods
5. Scientists detect presence of marburg virus in african fruit bats
6. Scientists Spot Brains Free Will Center
7. Scientists ID Likely Culprit in Popcorn Lung
8. Scientists explain how insulin secreting cells maintain their glucose sensitivity
9. Scripps Research scientists shed new light on how antibodies fight HIV
10. Scientists, physicians present latest findings in personalized cancer treatment and prevention
11. Scientists demonstate link between genetic variant and effectiveness of smoking cessation meds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2008)...-five day OnBase deployment critical in electronic...efit patients, CLEVELAND, July 9 /PRNewswire/ -- ...rise document management software suite, announced...sults since the deployment of,OnBase in March. Bas... four,states, SSM is a forward-thinking health car...
(Date:7/9/2008)...NTO, July 9 /PRNewswire-FirstCall/ - MDS Inc. (TSX...and services to the global life,sciences markets, ...f,Canada Limited (AECL) with notice of arbitration...el AECL to fulfill its contractual obligations,und... (ILTSA) and if not,granted, seeking significant m...
(Date:7/9/2008)... DRE, Inc., a premier internation...s its customers that as much as $250,000 in medica...come tax filings. , Louis...mulus Act of 2008, in accordance with Tax Code Sec...al equipment bought in 2008. This could make 2008 ...
(Date:7/9/2008)... InsuranceSpecialists.com, a lead...or almost a decade, now offers comprehensive infor...idential candidates are taking on health reform as...ment-free, supplies unbiased material on medical, ...elp consumers make the best choices in coverage fo...
Breaking Medicine News(10 mins):Health News:SSM Health Care Upgrades Patient Care With Speedy Document Management Implementation 2Health News:SSM Health Care Upgrades Patient Care With Speedy Document Management Implementation 3Health News:MDS Commences Arbitration against AECL over Cancelled MAPLE Project and Files $1.6 Billion Court Claim against AECL and the Government of Canada 2Health News:MDS Commences Arbitration against AECL over Cancelled MAPLE Project and Files $1.6 Billion Court Claim against AECL and the Government of Canada 3Health News:Economic Stimulus Act Can Improve Medical Equipment Purchasing Power 2Health News:InsuranceSpecialists.com Looks at the Candidates and Health Reform 2Health News:InsuranceSpecialists.com Looks at the Candidates and Health Reform 3
...ir findings in the current Biology online on Febru...f a protein that plays// key roles in the control ...hibitor can halt the growth of tumors in mice and ...e. The findings are reported in companion papers...
...latest issue of the medical journal The Lancet cla...fects on arthritics//. This research carried out b...ience Foundation independently. Patients sufferin...oidal anti-inflammatories (NSAIDS) like Aspirin an...
...ucted by British researchers, breast fed babies ha...ed counterparts//. This once again goes on to prov...tudy was conducted by Institute of Child Health in...group of four to six. In this group, 184 children...
...vasively identify women at risk for preterm birth,...tal adrenal glands//, according to an abstract pre...he Society for Maternal-Fetal Medicine Conference ... major public health problem with lasting repercus...
Other Medicine News:Health News:New Protein Inhibitor Halts Growth Of Cancerous Cells 2
(Date:7/6/2008)...rketing Authorization Application currently ...E, July 7 /- Cell Therapeut...ced the publication of results from its,randomized...poliglumex,CT-2103) with gemcitabine or vinorelbi...) patients with previously untreated non-small cel...
(Date:7/3/2008)...ewswire-USNewswire/ -- All newborn infants,should ...esent at birth,according to a new recommendation ...recommendation and the accompanying summary of evi...Children whose hearing is impaired at birth, durin...with verbal and nonverbal communication and,social...
(Date:7/3/2008)...MBRIDGE Massachusetts, July 3,/PRNewswire-FirstCal...ology company, Jerini AG for an equity purchase p...a (HAE) product, FIRAZYR(R), to its Human Genetic... global sales expected to be around $350-400 mill...ve environment, - Expected to be accretive for No...
(Date:7/2/2008)...y Endpoint Met in Stage 1 of Two-Stage Study ...ble Patients to Date Continue to Show Objective Tu...e -, TUSTIN, Calif., July 2 /PRNewswire-FirstCall...M ) today reported that its lead product,candidate...imary endpoint,in its ongoing Phase II clinical tr...
Breaking Medicine Technology:Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 2Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 3Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 4Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 5Task Force Recommends Screening for Hearing Loss in All Newborns 2Task Force Recommends Screening for Hearing Loss in All Newborns 3Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent 2Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent 3Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent 4Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent 5Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent 6Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent 7Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent 8Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer 2Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer 3Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer 4CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation 139 1CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation 139 2CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation 139 3International study strengthens case for daily calcium pill 195 1International study strengthens case for daily calcium pill 195 2Methamphetamine study suggests increased risk for HIV transmission 192 1Methamphetamine study suggests increased risk for HIV transmission 192 2Embryonic Stem Cells Repair Human Heart 190 1Embryonic Stem Cells Repair Human Heart 190 2Embryonic Stem Cells Repair Human Heart 190 3
...Presented at Society of Nuclear,Medicine Annual Me...stCall/ --,Immunomedics, Inc. , a biopharmaceutica...ies to treat cancer and other serious,diseases, to...en,(CEA) antibody, labetuzumab, labeled with the r...active when given in two doses,to patients with co...
...omide in Multiple Myeloma,Presented at the America..., CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ --...ults of a Phase III study,demonstrating that the a...s overall survival (OS) by 17.6 months in patients...eloma compared to the,current standard of care. Th...
Other Medicine Technology:Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 2Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 3Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 4Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 5Adding Thalidomide to Standard Therapy Improves Survival in Newly,Diagnosed Multiple Myeloma Patients Over Age 75 2Adding Thalidomide to Standard Therapy Improves Survival in Newly,Diagnosed Multiple Myeloma Patients Over Age 75 3Adding Thalidomide to Standard Therapy Improves Survival in Newly,Diagnosed Multiple Myeloma Patients Over Age 75 4Adding Thalidomide to Standard Therapy Improves Survival in Newly,Diagnosed Multiple Myeloma Patients Over Age 75 5Adding Thalidomide to Standard Therapy Improves Survival in Newly,Diagnosed Multiple Myeloma Patients Over Age 75 6
...ecifically to enable direct inspection of the peri... applications as well. Its insertion tube and dist...nsertion into the peripheral bronchi can be accomp...ated scope offers high-resolution and brightness, ...
Double lumen tubes for selective one-lung ventilation., ,Each SHER-I-BRONCH Endobronchial Tube is packaged with pre-loaded stylet, tube-to-circuit adaptors, suction catheters and Accessories Pack (f
Used for endobronchial blockade of the left or right lung for procedures which require one-lung ventilation. The set consists of an endobronchial blocker catheter and an Arndt Multiport Airway Adapte
...tablish emergency airway access through the cricot...s a 12 gauge x 3" Angiocath I.V. catheter, which i...to ventilate. Designed to be used with the liter f...milar to the Cook Emergency Cricothyrotomy Kit, bu...
Medicine Products: